Red X iconGreen tick iconYellow tick icon
The University of Otago is launching a new brand. Find out more
Skip to main content Skip to side navigation

BMedSc MB ChB(Otago) PhD(Monash) FRACP

Department of Internal MedicineRussel Scott image
Christchurch Hospital
Private Bag 4710
Christchurch
New Zealand

Email russell.scott@cdhb.govt.nz

Current Roles

  • Clinical Professor of Medicine, University of Otago, Christchurch, New Zealand
  • Consulting Physician: Diabetes, Endocrinology and Metabolism
  • Physician, Internal Medicine, Canterbury District Health Board
  • Consultant, NZ Clinical Research OpCo Ltd

Research Interests

  • Prevention and treatment of type 1 Diabetes Mellitus
  • Lipid disorders and cardiovascular disease
  • Complications and treatment of Type 2 diabetes
  • Novel metabolic treatment strategies
  • Gene editing and disease modification

Top 10 Publications

  • Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, Hovingh GK, Cariou B, Gouni-Berthold I, Somaratne R, Bridges I, Scott R, Wasserman SM, Gaudet D; for the RUTHERFORD-2 Investigators.  PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.   Lancet 2015: 385(9965), 331-40.
  • Sharma A, Green JB, Dunning A, Lokhnygina Y, Al-Khatib SM, Lopes RD, Buse JB, Lachin JM, Van de Werf F, Armstrong PW, Kaufman KD, Standl E, Chan JCN, Distiller LA, Scott R, Peterson ED, Holman RR; TECOS Study Group. Causes of Death in a Contemporary Cohort of Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights from the TECOS Trial. Diabetes Care. 2017: 40(12), 1763-1770.
  • Scott R, Morgan J, Zimmer Z, Lam RLH, O'Neill EA, Kaufman KD, Engel SS, Raji A. A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study. Diabetes Obes Metab. 2018: 20(12), 2876-2884.
  • Cao JY, Waldman B, O'Connell R, Sullivan DR, Scott RS, Aryal N, Gebski V, Marschner I, Taskinen MR, Simes JR, McGill N, Jenkins AJ, Keech AC; FIELD investigators. Uric acid predicts long-term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD study. Diabetes Obes Metab. 2020: 22(8),1388-1396.
  • Page MM, Ekinci EI, Burnett JR, Hooper AJ, Reid N, Bishop W, Florkowski CM, Scott R, O'Brien RC, Watts GF. Lipoprotein apheresis and PCSK9 inhibitors for severe familial hypercholesterolaemia: Experience from Australia and New Zealand. J Clin Apher. 2021: 36(1), 48-58.
  • Ong KL, Wu L, Januszewski AS, O'Connell R, Xu A, Scott RS, Sullivan DR, Rye KA, Li H, Ma RC, Li L, Gebski V, Jenkins AJ, Jia W, Keech AC. The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-study. Diab Vasc Dis Res. 2021: 18(4) 14791641211032547.
  • Willis J, Cunningham-Tisdall C, Griffin C, Scott R, Darlow BA, Owens N, Ferguson J, Mackenzie K, Williman J, de Bock M. Type 1 diabetes diagnosed before age 15 years in Canterbury, New Zealand: A 50 year record of increasing incidence. Pediatr Diabetes. 2021: 23(3), 301-309.

    Quinn N, Januszewski AS, Brazionis L, O'Connell R, Aryal N, O'Day J, Scott R, Mitchell P, Jenkins AJ, Keech AC.  Fenofibrate, which reduces risk of sight-threatening diabetic retinopathy in type 2 diabetes, is associated with early narrowing of retinal venules: a FIELD trial substudy. FIELD Trial Study Group. Intern Med J. 2022: 52(4), 676-679.
  • Tetri Mak LY, Gane E, Schwabe C, Yoon KT, Heo J, Scott R, Lee JH, Lee JI, Kweon YO, Weltman M, Harrison SA, Neuschwander BA, Cusi K, Loomba R, Given BD, Christianson DR, Garcia-Medel E, Yi M, Hamilton J, Yuen MF. A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis. J Hepatol. 2023: 78(4), 684-692.
  • Watts GF, Schwabe C, Scott R, Gladding PA, Sullivan D, Baker J, Clifton P, Hamilton J, Given B, Melquist S, Zhou R, Chang T, San Martin J, Gaudet D, Goldberg IJ, Knowles JW, Hegele RA, Ballantyne CM. RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts.. Nat Med. 2023: 29(9), 2216-2223.
  • Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial. Raal F, Fourie N, Scott R, Blom D, De Vries Basson M, Kayikcioglu M, Caldwell K, Kallend D, Stein E; LIBerate-HeFH Investigators. Eur Heart J. 2023: 44(40), 4272-4280.

Publications

Back to top